iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patients with unmet medical need.
iOnctura is uncovering the key to unlock difficult to treat tumors burdened by stroma and immune mediated resistance. We do this by interrogating new mechanisms that disrupt the dynamic interplay at the heart of the tumor-stroma-immune interface.
iOnctura awarded UK’s MHRA Innovation Passport for entry into innovative licensing and access pathway (ILAP)
iOnctura announces publication of pioneering research describing the unique biological features of roginolisib
iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program